Dr. Lowell Anthony, MD, FACP
Claim this profileUniversity of Kentucky/Markey Cancer Center
Studies Neuroendocrine Tumors
Studies Carcinoid Tumor
5 reported clinical trials
6 drugs studied
Area of expertise
1Neuroendocrine Tumors
Stage IV
Stage III
2Carcinoid Tumor
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Lowell Anthony, MD, FACP is currently running
Triapine + Targeted Radiation
for Neuroendocrine Cancer
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
Recruiting1 award Phase 2
Targeted Alpha-Particle Therapy
for Neuroendocrine Tumors
This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Recruiting1 award Phase 1 & 213 criteria
More about Lowell Anthony, MD, FACP
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Lowell Anthony, MD, FACP has experience with
- Lutetium Lu 177 Dotatate
- Peposertib
- Triapine
- Cabozantinib S-malate
- Everolimus
- [212Pb]VMT-α-NET
Breakdown of trials Lowell Anthony, MD, FACP has run
Neuroendocrine Tumors
Carcinoid Tumor
Uterine Tumors
Gastrointestinal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lowell Anthony, MD, FACP specialize in?
Lowell Anthony, MD, FACP focuses on Neuroendocrine Tumors and Carcinoid Tumor. In particular, much of their work with Neuroendocrine Tumors has involved Stage IV patients, or patients who are Stage III.
Is Lowell Anthony, MD, FACP currently recruiting for clinical trials?
Yes, Lowell Anthony, MD, FACP is currently recruiting for 3 clinical trials in Lexington Kentucky. If you're interested in participating, you should apply.
Are there any treatments that Lowell Anthony, MD, FACP has studied deeply?
Yes, Lowell Anthony, MD, FACP has studied treatments such as Lutetium Lu 177 Dotatate, Peposertib, Triapine.
What is the best way to schedule an appointment with Lowell Anthony, MD, FACP?
Apply for one of the trials that Lowell Anthony, MD, FACP is conducting.
What is the office address of Lowell Anthony, MD, FACP?
The office of Lowell Anthony, MD, FACP is located at: University of Kentucky/Markey Cancer Center, Lexington, Kentucky 40536 United States. This is the address for their practice at the University of Kentucky/Markey Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.